Stem cell injections for back pain are still a research treatment. Several randomized trials have injected mesenchymal stem cells or related cells into degenerated lumbar discs, and the results so far are mixed: some studies report lower pain scores than controls, while the largest published trial did not meet its primary endpoint. As of November 2026, the FDA states that no regenerative medicine therapy is approved for disc disease or back pain, and none of the regenerative medicine products on Japan's PMDA approval lists is approved for back pain or disc disease.
This article explains what disc problems are, what the cell trials actually tested, how to read the evidence, and how the treatment is handled in Japan and the US.
Back pain and disc degeneration in plain terms
The spine is a stack of vertebrae. Between them sit intervertebral discs, cushion-like pads that absorb shock and keep the bones apart. The US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) describes two disc problems that matter here:
- Disc degeneration: with age the discs break down, often alongside arthritis or narrowing of the spinal canal (spinal stenosis).
- Herniated or ruptured disc: a disc compresses and irritates nearby nerves; this often happens in the lower (lumbar) spine.
NIAMS classes back pain by how long it lasts. Acute pain lasts a few days to a few weeks; subacute pain lasts 4 to 12 weeks; chronic pain lasts longer than 12 weeks. It also notes that several factors often act together, and sometimes no specific cause is found. That last point matters for any disc treatment: a worn disc on an MRI is common, and it is not always the source of a person's pain. Trials therefore try to select patients whose pain is judged to come from the disc itself, often called discogenic pain.
Standard care comes first. NIAMS lists medicines (including injections for certain types of back pain), cold or heat, limiting activity rather than bed rest, physical therapy, and lifestyle changes, with surgery (such as discectomy, spinal fusion or disc replacement) considered when other treatments have not helped. It states that most people find relief within six weeks.
What cell approaches are being studied
The idea behind cell therapy for discs is that the inner part of a degenerated disc loses cells and water, and that injected cells might slow or alter that process or change the inflammation that drives pain. Most trials use mesenchymal stem cells (MSCs) or a closely related cell type called mesenchymal precursor cells. For background on where these cells come from, see Mesenchymal Stem Cells Explained.

The main variables across studies are:
| Variable | What researchers have tested |
|---|---|
| Cell source | The patient's own bone marrow cells (autologous) or cells from a donor (allogeneic) |
| Delivery | A single injection into the disc (intradiscal), sometimes with a carrier such as hyaluronic acid |
| Patients | Usually chronic low back pain from moderate degeneration at one disc level, after conservative care has not helped |
| Comparator | Saline injection, a sham injection near the spine, or no control at all |
Two points stand out. First, the trials mostly enrolled people with degenerative disc disease, not people with an acute herniated disc and leg pain, so evidence for "stem cells for a herniated disc" is thinner still. Second, many studies had no control group, which makes it hard to separate any effect of the cells from natural improvement, placebo response or other care.
What the main trials found
Small randomized trial, Spain (2017)
Noriega and colleagues, writing in Transplantation, randomized 24 patients with chronic back pain from lumbar disc degeneration who had not responded to conservative treatment. Half received donor bone marrow MSCs injected into the disc; half received a sham injection into the muscles beside the spine. Over one year, the authors reported that the procedure was feasible and safe, that the MSC group improved on pain and function scores, mainly among a subset of responders, and that an MRI disc grading score improved in the MSC group. They concluded that donor MSC therapy "may be a valid alternative", which is a cautious statement from a pilot-size trial.
Mesenchymal precursor cell trials
A 2021 study in The Spine Journal (Amirdelfan and colleagues) randomized 100 patients with chronic low back pain from moderate disc degeneration across 13 sites (12 in the US, 1 in Australia) to donor mesenchymal precursor cells or to hyaluronic acid or saline controls, and followed them for 36 months. The authors reported better pain and function scores than controls at various time points, with no significant difference between groups in disc degeneration scores or adverse event rates.
The larger follow-up trial was published in The Spine Journal in 2025 (Beall and colleagues). It randomized 404 patients at 49 sites to cells alone, cells with hyaluronic acid, or a saline injection, with 36 months of follow-up. The authors state that the primary efficacy endpoint did not reach significance for either treatment group, and that no secondary endpoints differed significantly in the full study population. In further analyses, cells with hyaluronic acid were associated with lower pain than saline at 12 and 24 months, with larger differences in patients whose pain had lasted less than 68 months. The treatment appeared safe in this trial.
The developer, Mesoblast, is running another sham-controlled phase 3 trial with a 12-month pain endpoint. Relaying company statements, the trade publication Biotech Dispatch reported in August 2026 that all 350 patients had been treated, that top-line results are expected in mid-2027, and that the product is not approved by the FDA.
What the systematic reviews say
- A 2023 meta-analysis in Frontiers in Bioengineering and Biotechnology (Zhang and colleagues) pooled 9 studies with 245 patients, most of whom received bone marrow MSCs. Only one was a randomized controlled trial; the rest were prospective cohort studies. The authors wrote that MSCs "may be effective" for discogenic pain, but also reported very high heterogeneity between studies, noted the small sample, and said large, long-term clinical studies are still needed.
- A 2024 review in Pain Physician (Manchikanti and colleagues) covered injections of MSCs and platelet-rich plasma (PRP) into the disc, drawing on 8 randomized trials and 8 observational studies. It rated the evidence as fair (Level III) and listed a shortage of high-quality studies as a limitation.
How to read this evidence
Put together, the research picture looks like this:
| Question | Where the evidence stands (November 2026) |
|---|---|
| Is it approved for back pain? | No approved product for back pain or disc disease in the US or Japan |
| Are there randomized, controlled trials? | Yes, a few, mostly small; the largest did not meet its primary endpoint |
| Do reviews show a consistent benefit? | Reviews describe possible benefit but rate the evidence as limited, with mixed study designs |
| Is disc structure restored? | Not shown consistently; the 2021 trial found no difference in disc degeneration scores |
| Safety | Published trials report no major safety signal, but samples are small and follow-up is limited |
Results are preliminary and mixed, and uncontrolled cohort studies are the weakest kind of evidence. Treatments offered at private clinics also vary in cell source, cell count, preparation and injection site, so a published trial result may not apply to a specific clinic's product.
Stemirac: approved in Japan for spinal cord injury, not back pain
Stemirac (ステミラック注), made by Nipro, is a Japanese cell product made from the patient's own bone marrow mesenchymal stem cells. It received conditional, time-limited approval (seven years) on 28 December 2018 for improving neurological symptoms and functional impairment associated with spinal cord injury. Nipro applied for full approval on 14 November 2025. Stemirac is not approved for back pain, disc degeneration or herniated discs, and a clinic offering stem cells for back pain is not offering Stemirac.

How Japan regulates stem cell treatment for back pain
Because no approved product in Japan covers back pain, a clinic that offers cell treatment for it does so as self-pay treatment under the Act on the Safety of Regenerative Medicine, in force since November 2014. Before treating anyone, the clinic must write a provision plan, have it reviewed by a certified committee and file it with the Ministry of Health, Labour and Welfare (MHLW). The risk class depends on the cells:
- The patient's own cultured stem cells (for example fat- or bone marrow-derived MSCs grown in a lab) are generally Class II.
- Cells from another person, such as donated umbilical cord cells, are Class I, the highest-risk class. After filing a Class I plan, the clinic must generally wait 90 days before treating patients.
- PRP injected into the spine is not a stem cell treatment; its class depends on how it is used, as set out in the clinic's filed plan.
A filed plan shows that the clinic has gone through the safety and procedural steps the law requires. It does not show that the treatment works for back pain. For how the classes and committees work, see How Japan regulates regenerative medicine and Regenerative Medicine in Japan: How the Safety Act Works. If you are considering a specific clinic, send its name to our advisors and we'll check whether it has filed a provision plan for that treatment.
The US position
The FDA states that the only stem cell products approved in the US are blood-forming stem cells from umbilical cord blood, for disorders of blood production, and that regenerative medicine therapies have not been approved for any orthopedic condition, naming disc disease and back pain among them. Unapproved products need FDA oversight in a clinical trial before approval, and the FDA warns of reported harms including infections, tumor formation and blindness. For a comparison with Japan's system, see Which Stem Cell Treatments Are FDA-Approved.
Questions to raise before any disc injection
If you are weighing a cell treatment for back pain, these questions help frame the conversation with your spine doctor and any clinic:

- Has my pain been traced to a specific disc, and what standard treatments have I already tried?
- Which cells would be used (my own or a donor's), and under which risk class is the treatment filed?
- Is it given as part of a study with a control group, or as self-pay care?
- What are the risks of the injection itself, such as infection or disc injury, and how are complications handled after I go home?
- What follow-up imaging and reviews are planned?
More general questions are in 10 Questions to Ask a Japanese Clinic and Stem Cell Therapy Side Effects and Risks.
For back and disc problems, a Japanese doctor first reviews your medical records to judge whether any treatment is appropriate. Our advisors work directly with Japanese hospitals and clinics and arrange record translation, a remote video consultation, an interpreter and follow-up at home. Consultation and coordination are free, and we reply within one working day. Our pre-screening is the place to start.
Frequently asked questions
Is stem cell therapy approved for back pain?
No; as of November 2026, no cell product is approved for back pain or disc disease in the US or Japan. The FDA states that no regenerative medicine therapy is approved for any orthopedic condition, including disc disease and back pain, and in Japan clinics offer it as self-pay treatment under a filed provision plan.
Can stem cells regrow a herniated or degenerated disc?
That has not been shown. Most trials studied degenerated discs rather than acute herniations, and the 2021 randomized trial of mesenchymal precursor cells found no significant difference in disc degeneration scores between groups.
What did the largest stem cell trial for back pain find?
The 404-patient trial published in 2025 did not meet its primary efficacy endpoint in the full study population. Further analyses reported lower pain than saline in some groups, and a new phase 3 trial is expected to report in mid-2027.
Is Stemirac used for back pain in Japan?
No. Stemirac (ステミラック注) is approved in Japan for spinal cord injury only, under a conditional, time-limited approval granted in December 2018.
What risk class is a stem cell back injection in Japan?
It depends on the cells. Treatments using the patient's own cultured stem cells are generally Class II, and treatments using donor cells, such as umbilical cord cells, are Class I. Details are on Getting treated in Japan and in our clinic directory.
Sources: NIAMS, Back Pain (reviewed February 2023); Noriega et al., Transplantation 2017; Amirdelfan et al., The Spine Journal 2021; Beall et al., The Spine Journal 2025; Zhang et al., Frontiers in Bioengineering and Biotechnology 2023; Manchikanti et al., Pain Physician 2024; Biotech Dispatch (18 August 2026); Nipro release (17 November 2025); PMDA lists of approved regenerative medicine products (fiscal 2015 to 2026); US FDA, Important Patient and Consumer Information About Regenerative Medicine Therapies (April 2024); MHLW page on regenerative medicine; Act on the Safety of Regenerative Medicine and its Enforcement Regulations (e-Gov). Checked November 2026; MHLW publications prevail.
Medical disclaimer: This site provides general information only and does not constitute medical advice; whether any treatment is suitable for you must be decided by a doctor after an in-person consultation.